


## Claims

1. A compound of formula (I)



wherein:

R<sup>1</sup> is C<sub>3-5</sub> alkyl optionally substituted by one or more halogen atoms;

R<sup>2</sup> is a phenyl group, optionally substituted by one or more fluorine atoms;

R<sup>3</sup> and R<sup>4</sup> are both hydroxy;

10 R is XOH, where X is CH<sub>2</sub>, OCH<sub>2</sub>CH<sub>2</sub> or a bond,  
or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt

provided that:

when X is CH<sub>2</sub> or a bond, R<sup>1</sup> is not propyl.

15 when X is CH<sub>2</sub> and R<sup>1</sup> is CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>, butyl or pentyl, the phenyl group at R<sup>2</sup> must be substituted by fluorine.

when X is OCH<sub>2</sub>CH<sub>2</sub> and R<sup>1</sup> is propyl, the phenyl group at R<sup>2</sup> must be substituted by fluorine.

20 2. A compound according to claim 1 in which R<sup>1</sup> is 3,3,3,-trifluoropropyl, butyl or propyl.

A 3. A compound according to claims 1 ~~or 2~~ in which R<sup>2</sup> is phenyl or 4-fluorophenyl or 3,4-difluorophenyl.

claim 1  
25 A 4. A compound according to ~~any one of claims 1 to 3~~ in which R is CH<sub>2</sub>OH or OCH<sub>2</sub>CH<sub>2</sub>OH.

46

5. A compound according to claim 1 which is:

[1R-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1R\*,2S\*),5 $\beta$ ]]-3-[7-[[2-(4-Fluorophenyl)cyclopropyl]amino]-5-[(3,3,3-trifluoropropyl)thio]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol;

[1R-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1R\*,2S\*),5 $\beta$ ]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-[(3,3,3-trifluoropropyl)thio]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol;

[1S-(1 $\alpha$ , 2 $\alpha$ , 3 $\beta$  (1S\*,2R\*),5 $\beta$ )]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol;

[1R-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1R\*,2S\*),5 $\beta$ ]]-3-[5-(Butylthio)-7-[[2-(3,4-difluorophenyl)cyclopropyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol;

[1S-[1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,4 $\alpha$ (1S\*,2R\*)]]-4-[5-(Butylthio)-7-[[2-(4-fluorophenyl)cyclopropyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol;

[1S-(1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1S\*,2R\*),5 $\beta$ )]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-[(3,3,3-trifluoropropyl)thio]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol;

[1S-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ ,5 $\beta$ (1S\*,2R\*)]]-3-(2-Hydroxyethoxy)-5-[7-(2-phenylcyclopropyl)amino]-5-[(3,3,3-trifluoropropyl)thio]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2-diol

[1S-[1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,4 $\alpha$ (1S\*, 2R\*)]]-4-[5-(Butylthio)-7-[[2-(3,4-difluorophenyl)cyclopropyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]cyclopentane-1,2,3-triol;

[1S-[1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ (1S\*,2R\*),5 $\beta$ ]]-3-[5-(Butylthio)-7-[(2-phenylcyclopropyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-cyclopentane-1,2-diol;

or pharmaceutically acceptable salts or solvates thereof, or solvates of such salts.

6. A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 5~~ <sup>claim 1</sup> in combination with a pharmaceutically acceptable diluent, adjuvant and/or carrier.

7. A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 5~~ <sup>claim 1</sup> for use in the treatment or prevention of myocardial infarction, thrombotic stroke, transient ischaemic attacks, and/or peripheral vascular disease.

8. A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 5~~ <sup>claim 1</sup> for use in the treatment or prevention of unstable or stable angina.

9. A compound according to ~~any one of claims 1 to 5~~ <sup>claim 1</sup> for use in therapy.

10. A compound according to ~~any one of claims 1 to 5~~ <sup>claim 1</sup> for use in the treatment or prevention of myocardial infarction, thrombotic stroke, transient ischaemic attacks, and/or peripheral vascular disease.

11. A compound according to ~~any one of claims 1 to 5~~ <sup>claim 1</sup> for use in the treatment or prevention of unstable or stable angina.

12. The use of a compound according to ~~any one of claims 1 to 5~~ <sup>claim 1</sup> as an active ingredient in the manufacture of a medicament for use in the treatment or prevention of myocardial infarction, thrombotic stroke, transient ischaemic attacks, and/or peripheral vascular disease.

13. The use of a compound according to ~~any one of claims 1 to 5~~ <sup>claim 1</sup> as an active ingredient in the manufacture of a medicament for use in the treatment or prevention of unstable or stable angina.

14. A method of treatment or prevention of a platelet aggregation disorder which comprises administering to a person suffering from or susceptible to such a disorder a therapeutically effective amount of a compound according to ~~any one of claims 1 to 5~~ <sup>claim 1</sup>.


15. A method of treatment or prevention of myocardial infarction, thrombotic stroke, transient ischaemic attacks, and/or peripheral vascular disease, which comprises administering to a person suffering from or susceptible to such a condition a therapeutically effective amount of a compound according to ~~any one of claims 1 to 5.~~ <sup>claim 1</sup>

5

16. A method of treatment or prevention of unstable or stable angina which comprises administering to a person suffering from or susceptible to such a condition a therapeutically effective amount of a compound according to ~~any one of claims 1 to 5.~~ <sup>claim 1</sup>


10

17. A process for the preparation of a compound of formula (I) which comprises reacting a compound of formula (II):



15

where R, R<sup>1</sup>, R<sup>3</sup> and R<sup>4</sup> are as defined in claim 1, or are protected derivatives thereof, or R<sup>3</sup> and R<sup>4</sup> together form a bond in the 5-membered ring, or R is CH<sub>2</sub>CH<sub>2</sub>OR' where R' is C<sub>1-6</sub> alkyl or benzyl, and L is a leaving group, with a compound of formula (III):



20

where R<sup>2</sup> is defined in claim 1 or is a protected derivative thereof, in the presence of a base in an inert solvent at ambient or elevated temperature, and optionally thereafter and in any order:

48

converting one or more functional groups into further functional groups;

removing any protecting groups;

forming a pharmaceutically acceptable salt or solvate, or a solvate of such a salt.

5 18. The compounds:

[3aR-[3a $\alpha$ ,4 $\alpha$ ,6 $\alpha$ (1R\*,2S\*),6a $\alpha$ ]]-6-[7-[[2-(4-Fluorophenyl)cyclopropyl]amino]-5-(propylsulphonyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-methanol;

10 [[3aR-[3a $\alpha$ ,4 $\alpha$ ,6 $\alpha$ (1R\*,2S\*),6a $\alpha$ ]]-6-[7-[[2-(4-Fluorophenyl)cyclopropyl]amino]-5-[(3,3,3-trifluoropropyl)thio]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-methanol;

[3aR-[3a $\alpha$ ,4 $\alpha$ ,6 $\alpha$ (1R\*,2S\*),6a $\alpha$ ]]-6-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-[(3,3,3-trifluoropropyl)thio]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-methanol;

15 [3aR-(3a $\alpha$ ,4 $\alpha$ ,6 $\alpha$ ,6a $\alpha$ )]-6-[7-Amino-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]-pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol;

[3aR-(3a $\alpha$ ,4 $\alpha$ ,6 $\alpha$ ,6a $\alpha$ )]-[[6-[7-Amino-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]-pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol]oxy]acetic acid, methyl ester;

20 [3aR-(3a $\alpha$ ,4 $\alpha$ ,6 $\alpha$ ,6a $\alpha$ )]-[[6-[7-Bromo-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]-pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol]oxy]acetic acid, methyl ester;

[3aR-[3a $\alpha$ ,4 $\alpha$ ,6 $\alpha$ (1R\*,2S\*),6a $\alpha$ ]]-[[6-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]-pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]acetic acid, methyl ester;

25 [3aR-[3a $\alpha$ ,4 $\alpha$ ,6 $\alpha$ (1R\*,2S\*),6a $\alpha$ ]]-6-[[7-[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol;

[3aR-(3a $\alpha$ ,4 $\alpha$ ,6 $\alpha$ ,6a $\alpha$ )]-6-[7-Amino-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-methanol;

30 [3aR-(3a $\alpha$ ,4 $\alpha$ ,6 $\alpha$ ,6a $\alpha$ )]-6-[7-Amino-5-(propylsulfonyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-methanol;



[3aR-(3α,4α,6α,6α)]-2-[6-[7-Amino-5-[(3,3,3-trifluoropropyl)thio]-3H-1,2,3-triazolo[4,5-d]-pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yloxy]ethanol;

5 [3aR-(3α,4α,6α,6α)]-2-[6-[7-Bromo-5-[(3,3,3-trifluoropropyl)thio]-3H-1,2,3-triazolo[4,5-d]-pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yloxy]ethanol;

[3aR-[3α,4α,6α(1R\*,2S\*),6α]]-2-[6-(7-Phenylcyclopropyl)amino]-5-[(3,3,3-trifluoropropyl)thio]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-1,3-dioxol-4-yloxy]ethanol;

10 [3aR-[3α,4α,6α(1R\*,2S\*),6α]]-6-[[7-[(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol;

[3aR-[3α,4α,6α(1R\*,2S\*),6α]]-6-[[7-[(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylsulfonyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol;

15 [3aR-[3α,4α,6α(1R\*,2S\*),6α]]-6-[5-(Butylthio)-7-[[2-(3,4-difluorophenyl)cyclopropyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol;

20 [3aS-(3α,4α,6α,6α)]-[Tetrahydro-6-hydroxy-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]-carbamic acid, phenylmethyl ester;

[3aS-(3α,4α,6α,6α)]-[2,2-Dimethyl-6-(2-hydroxyethoxy)-tetrahydro-4H-cyclopenta-1,3-dioxol-4-yl]-carbamic acid, phenylmethyl ester;

[3aR-(3α,4α,6α,6α)]-2-[6-Amino-2,2-dimethyl-tetrahydro-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol;

25 2-(Butylthio)-4,6-dichloropyrimidine-5-amine;

[3aR-(3α,4α,6α,6α)]-2-[6-[[5-Amino-2-(butylthio)-6-chloro-pyrimidin-4-yl]amino]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]ethanol;

[3aR-[3α,4α,6α(1R\*,2S\*),6α]]-2-[6-[[5-(Butylthio)-7-chloro-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol;

